A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab

References

• Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):1–4. doi: 10.1111/bjd.18921.
   PubMed Web of Science ®Google Scholar
• Cifuentes L, Kiritsi D, Chen W, et al. A case of junctional epidermolysis bullosa with prurigo-like lesions and reduction of collagen XVII and filaggrin. Br J Dermatol. 2013;169(1):195–198. doi: 10.1111/bjd.12241.
   PubMed Web of Science ®Google Scholar
• Bauer JW, Lanschuetzer C. Type XVII collagen gene mutations in junctional epidermolysis bullosa and prospects for gene therapy. Clin Exp Dermatol. 2003; 28(1):53–60. doi: 10.1046/j.1365-2230.2003.01192.x.
   PubMed Web of Science ®Google Scholar
• Condrat I, He Y, Cosgarea R, et al. Junctional epidermolysis bullosa: allelic heterogeneity and mutation stratification for precision medicine. Front Med (Lausanne). 2018;5:363. doi: 10.3389/fmed.2018.00363.
   PubMed Web of Science ®Google Scholar
• McGrath JA, Gatalica B, Christiano AM, et al. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat Genet. 1995;11(1):83–86. doi: 10.1038/ng0995-83.
   PubMed Web of Science ®Google Scholar
• Keith AR, Twaroski K, Ebens CL, et al. Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa. Expert Opin Biol Ther. 2020;20(8):911–923. doi: 10.1080/14712598.2020.1740678.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi: 10.1056/NEJMoa1314768.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou M, Zhang L, et al. Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: a case report. Dermatol Ther. 2021;34(6):e15130. Novdoi: 10.1111/dth.15130.
   PubMed Web of Science ®Google Scholar
• Caroppo F, Milan E, Giulioni E, et al. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab. J Eur Acad Dermatol Venereol. 2022;36(5):e365–e367. doi: 10.1111/jdv.17887.
   PubMed Web of Science ®Google Scholar
• Wu XG, Yan S, Jiang JQ, et al. Successful treatment of epidermolysis bulls parmigiano by unplumbed. J Dermatol. 2023;50(6):837–842. doi: 10.1111/1346-8138.16729.
   PubMed Web of Science ®Google Scholar
• Yu L, Wang JB, Bian L, et al. Dystrophic epidermolysis bullosa pruriginosa: successfully treated with dupilumab. Dermatitis. 2023;34(1):58–59. doi: 10.1089/DERM.0000000000000954.
   PubMed Web of Science ®Google Scholar
• Shehadeh W, Sarig O, Bar J, et al. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab. Br J Dermatol. 2020;182(6):1495–1497. doi: 10.1111/bjd.18855.
   PubMed Web of Science ®Google Scholar
• Zhou AG, Little AJ, Antaya RJ. Epidermolysis bullosa pruriginosa treated with dupilumab. Pediatr Dermatol. 2021; 38(2):526–527. doi: 10.1111/pde.14493.
   PubMed Web of Science ®Google Scholar
• Darbord D, Hickman G, Pironon N, et al. Dystrophic epidermolysis bullosa pruriginosa: a new case series of a rare phenotype unveils skewed Th2 immunity. J Eur Acad Dermatol Venereol. 2022;36(1):133–143. doi: 10.1111/jdv.17671.
   PubMed Web of Science ®Google Scholar
• Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol. 2023;188(1):12–21. doi: 10.1093/bjd/ljac001.
   PubMed Web of Science ®Google Scholar
• Chen F, Wei R, Deng D, et al. Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from China. J Eur Acad Dermatol Venereol. 2023;37(2):411–419. doi: 10.1111/jdv.18692.
   PubMedGoogle Scholar
• Herisse AL, Charlesworth A, Bellon N, et al. Genotypic and phenotypic analysis of 34 cases of inherited junctional epidermolysis bullosa caused by COL17A1 mutations. Br J Dermatol. 2021;184(5):960–962. doi: 10.1111/bjd.19752.
   PubMed Web of Science ®Google Scholar
• Snauwaert JJ, Yuen WY, Jonkman MF, et al. Burden of itch in epidermolysis bullosa. Br J Dermatol. 2014;171(1):73–78. doi: 10.1111/bjd.12885.
   PubMed Web of Science ®Google Scholar
• Papanikolaou M, Onoufriadis A, Mellerio JE, et al. Prevalence, pathophysiology and management of itch in epidermolysis bullosa. Br J Dermatol. 2021;184(5):816–825. doi: 10.1111/bjd.19496.
   PubMed Web of Science ®Google Scholar
• Breitenbach JS, Rinnerthaler M, Trost A, et al. Transcriptome and ultrastructural changes in dystrophic epidermolysis bullosa resemble skin aging. Aging (Albany NY). 2015;7(6):389–411. doi: 10.18632/aging.100755.
   PubMedGoogle Scholar
• Clawson RC, Duran SF, Pariser RJ. Epidermolysis bullosa pruriginosa responding to dupilumab. JAAD Case Rep. 2021; 16:69–71. doi: 10.1016/j.jdcr.2021.07.036.
   PubMedGoogle Scholar
• He H, Olesen CM, Pavel AB, et al. Tape-strip proteomic profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers. Front Immunol. 2020;11:1768. doi: 10.3389/fimmu.2020.01768.
   PubMed Web of Science ®Google Scholar
• Lettner T, Lang R, Bauer JW, et al. Increased levels of matrix metalloproteinase-9 and interleukin-8 in blister fluids of dystrophic and junctional epidermolysis bullosa patients. J Eur Acad Dermatol Venereol. 2015;29(2):396–398. doi: 10.1111/jdv.12399.
   PubMed Web of Science ®Google Scholar